Research suggests that family history explains conflicting study results for Alzheimer’s disease risk gene TOMM40.
Zebinix (eslicarbazepine acetate) has received market authorization as a once-daily monotherapy in adults with newly diagnosed partial-onset epilepsy.
A new first-of-its-kind study will assess Zika virus as a tool to target glioblastomas, one of the most challenging cancers to treat.
Research suggests increasing synaptic activity could alleviate SMA symptoms: motor function of mice was improved when treated with a glutamate receptor stimulant.
A patient with bilateral essential tremor has recently become the first patient in Pennsylvania (USA) to be successfully treated with a new, non-invasive, MR-guided focused ultrasound treatment.
Both lithium and rapamycin could prevent the secondary nerve cell damage caused by the overproduction of glutamate after a traumatic brain injury.
Restoration of CB1 signaling in aging individuals could become an effective treatment for age-related cognitive impairments.
The Biogerontology Research Foundation looks to deep-learning and artificial intelligence to accelerate drug discovery for aging and age-associated diseases, including neurodegenerative disease.
The European Commission has approved dinutuximab beta for the treatment of high-risk neuroblastoma patients over the age of 12 months, making it the only approved immunotherapy for these patients in Europe.
Researchers observe clinically silent hippocampal seizures in two Alzheimer’s disease patients during sleep; a period critical for memory consolidation.